Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Decades have passed since the first nanoparticles-base medicine was approved for human
cancer treatment, and the research and development of nanoparticles for drug delivery are …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

Messenger RNA (mRNA) has received great attention in the prevention and treatment of
various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA …

Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …

Vaccines are one of the most important tools in public health and play an important role in
infectious diseases control. Owing to its precision, safe profile and flexible manufacturing …

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …